Opinion statement
Anaplastic thyroid carcinoma (ATC) is a rare, highly aggressive tumor characterized by rapid growth that causes death soon after diagnosis. Optimal treatment is debatable because of inherent difficulties investigating a rare malignancy associated with a survival of only months. Nevertheless, there is evidence that a multimodality approach consisting of surgery, chemotherapy, and radiotherapy is the preferred approach when the disease is localized. Eradication by complete surgical resection with total thyroidectomy, although often not feasible, followed or preceded by concurrent doxorubicin-based chemotherapy and hyperfractionated external beam radiation has been occasionally used and can rarely be associated with long-term survival. Surgical extirpation with radical organ resection is associated with high morbidity, and, although an aggressive surgical approach is reasonable in selected patients, organ preservation should be the goal in a disease with high recurrence and death rates. Any modality used in isolation usually fails to control local and regional ATC. In otherwise healthy patients who can tolerate aggressive therapy, chemoradiation and surgery may also be warranted for palliating incurable disease in the neck, which can cause death by asphyxiation.
Similar content being viewed by others
References and Recommended Reading
Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics 1999. CA Cancer J Clin 1999, 49:8–31.
Venkatesh S, Ordonez NG, Schultz PN, et al.: Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer 1990, 66:321–330. The largest single institution experience provides an excellent clinicopathologic correlate to outcome of patients with ATC.
Rosen IB, Asa SL, Brierley JD: Anaplastic carcinoma of the thyroid gland. In Textbook of Endocrine Surgery. Edited by Clark OH, Duh Q-Y. Philadelphia: WB Saunders; 1997:127–132.
Carcangiu ML, Steeper T, Zampi G, Rosai J: Anaplastic thyroid carcinoma: a study of 70 cases. Am J Clin Pathol 1985, 83:135–138. Accompanies reference #2 as an authoritative study on the histopathology and the differential diagnosis of ATC.
Haigh PI, Ituarte P, Wu H-S, et al.: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemoradiation is associated with prolonged survival. Cancer 2000, in press.
Nilsson O, Lindeberg J, Zedenius J, et al.: Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25 year period. World J Surg 1998, 22:725–730. This article provides a chronology of the extensive experience by leaders in the field at the Karolinska Hospital in Stockholm, Sweden in treating ATC using a multimodality approach.
Lo CY, Lam KY, Wan KY: Anaplastic carcinoma of the thyroid. Am J Surg 1999, 177:337–339.
Tan RK, Finley RK III, Driscoll D, et al.: Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995, 17:41–48.
Junor EJ, Paul J, Reed NS: Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992, 18:83–88.
Demeter JG, De Jong SA, Lawrence AM, Paloyan E: Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991, 110:956–963.
Spires JR, Schwartz MR, Miller RH: Anaplastic thyroid carcinoma: association with differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 1988, 114:40–44.
Kim JH, Leeper RD: Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination adriamycin and radiation therapy: a new approach. Cancer 1983, 52:954–957.
Aldinger KA, Samaan NA, Ibanez M, Hill CS: Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978, 41:2267–2275.
Jereb B, Stjernsward J, Lowhagen T: Anaplastic giant cell carcinoma of the thyroid: a study of treatment and prognosis. Cancer 1975, 35:1293–1295.
Tennvall J, Lundell G, Hallquist A, et al.: Hyperfractionated radiotherapy and surgery in anaplastic thyroid carcinoma: report on two protocols. Cancer 1994, 74:1348–1354. A detailed study on the use of surgery and preoperative chemoradiation therapy to improve local control of ATC.
Schlumberger M, Parmentier C, Delisle M-J, et al.: Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991, 67:564–566.
Kobayashi T, Asakawa H, Umeshita K, et al.: Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996, 18:36–41.
Hadar T, Mor C, Shvero J, et al.: Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 1993, 19:511–516.
Goldman JM, Goren EN, Cohen MH, et al.: Anaplastic thyroid carcinoma: long-term survival after radical surgery. J Surg Oncol 1980, 14:389–394.
Nel CJC, vanHeerden JA, Goellner JR, et al.: Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc 1985, 60:51–58.
Mitchell G, Huddart R, Harmer C: Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1999, 50:33–38.
Simpson WJ: Anaplastic thyroid carcinoma: a new approach. Can J Surg 1980, 23:25.
Tennvall J, Tallroth E, El-Hassan A, et al.: Anaplastic thyroid carcinoma: doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncol 1990, 29:1025.
Voutilainen PE, Multanen M, Haapiainen RK, et al.: Anaplastic thyroid carcinoma survival. World J Surg 1999, 23:975–979.
Tallroth E, Wallin G, Lundell G, et al.: Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 1987, 60:1428–1431.
American Joint Committee on Cancer: Thyroid Gland. In AJCC Cancer Staging Manual. Edited by Fleming ID, Cooper JS, Henson DE, et al. Philadelphia: Lippincott-Raven; 1997:59–61.
Ain KB, Tofiq S, Taylor KD: Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 1996, 81:3650–3653.
Hama Y, Shimizu T, Hosaka S, et al.: Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetylcarbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Exp Toxicol Pathol 1997, 49:239–247.
Yeung SC, Xu G, Pan J, et al.: Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 2000, 60:650–656.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haigh, P.I. Anaplastic thyroid carcinoma. Curr. Treat. Options in Oncol. 1, 353–357 (2000). https://doi.org/10.1007/s11864-000-0051-8
Issue Date:
DOI: https://doi.org/10.1007/s11864-000-0051-8